ArticleCell cycle (Georgetown, Tex.)2011
RUNX1 and its understudied role in breast cancer.
Article in Cell cycle (Georgetown, Tex.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 73 citations in OpenAlex.
- Down-regulation of lncRNA-NEF indicates poor prognosis in intrahepatic cholangiocarcinoma.Bioscience reports · 2019Trial
- New players in the landscape of renal cell carcinoma bone metastasis and therapeutic opportunities.International journal of cancer · 2025Review
- Interface-guided phenotyping of coding variants in the transcription factor RUNX1.Cell reports · 2024Article
- Genetic analysis of PALB2 gene WD40 domain in canine mammary tumour patients.Veterinary medicine and science · 2024Article
- Runt-related transcription factors in human carcinogenesis: a friend or foe?Journal of cancer research and clinical oncology · 2023Review
- USP10 deubiquitinates RUNX1 and promotes proneural-to-mesenchymal transition in glioblastoma.Cell death & disease · 2023Article
- Review
- RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors.Molecules and cells · 2022Article
- NETWORK DIFFERENTIAL CONNECTIVITY ANALYSIS.The annals of applied statistics · 2022Article
- Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells.Nature communications · 2022Article
- Emerging Roles of Long Noncoding RNAs in Breast Cancer Epigenetics and Epitranscriptomics.Frontiers in cell and developmental biology · 2022Review
- Article
- Protein phase separation: A novel therapy for cancer?British journal of pharmacology · 2020Review
- Article
- Uncovering missed indels by leveraging unmapped reads.Scientific reports · 2019Article
- Profiling the epigenetic interplay of lncRNA RUNXOR and oncogenic RUNX1 in breast cancer cells by gene in situ cis-activation.American journal of cancer research · 2019Article
- Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.Breast cancer research : BCR · 2018Article
- Nuclear organization mediates cancer-compromised genetic and epigenetic control.Advances in biological regulation · 2018Review
- Loss of RUNX1 is associated with aggressive lung adenocarcinomas.Journal of cellular physiology · 2018Article
- Applying Expression Profile Similarity for Discovery of Patient-Specific Functional Mutations.High-throughput · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The transcription factor Runt-related transcription factor 1 (RUNX1) is critical for the earliest steps of hematopoiesis. RUNX1 was originally identified as a gene fusion in acute myeloid leukemia (AML) and thus has garnered heavy attention as a tumor suppressor in hematopoietic malignancies. However, RUNX1 is also strongly expressed in breast epithelia and may be misregulated during tumorigenesis. Here, I discuss our recent work implicating RUNX1 in proliferation control during breast epithelial-acinar morphogenesis. My goal is to place these findings in the context of a handful of other reports, which together argue that RUNX1 could act as a tumor suppressor gene in breast cancer. Testing this hypothesis requires focused in vivo studies, because the major commercial platform for global mRNA expression profiling does not reliably reflect RUNX1 levels. Our in vitro results indicate that hyperproliferation in RUNX1-deficient breast epithelia relies on another family of transcription factors, the Forkhead box O (FOXO) proteins. FOXOs could, therefore, represent a synthetic-lethal target for RUNX1-deficient tumors if the hypothesized link to breast cancer is correct.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.